Introduction
The adage “what gets measured gets managed” is a cornerstone of effective Infection Prevention and Control (IPC). Surveillance — the systematic collection and analysis — is central to IPC, providing the evidence needed to prioritise, implement, and evaluate interventions.
Without timely, high-quality data, efforts to prevent healthcare-associated infections (HCAIs) and combat antimicrobial resistance (AMR) risk being delayed, misdirected, or incomplete. This review synthesises evidence on the clinical and economic value of surveillance and its strategic role in building resilient healthcare systems.
The Global Burden of Inaction
HCAIs and AMR represent urgent threats to patient safety and healthcare sustainability. An estimated 136 million healthcare-associated, antibiotic-resistant infections occur annually¹, resulting in billions of dollars in direct treatment costs².
Each case extends hospital stays by an average of 7.8 days³, increasing morbidity and straining health system resources. Surveillance is essential for quantifying this burden, identifying trends, and enabling targeted interventions to reduce both clinical risk and financial cost.
What Do We Mean by Surveillance?
Surveillance in IPC is defined as:
“The ongoing, systematic collection, analysis, interpretation, and dissemination of data regarding a health-related event for use in public health action”; both process measures (e.g., hand hygiene compliance) and outcome measures (e.g., infection rates) are crucial for evaluating intervention⁴.
The CDC outlines four pillars of effective surveillance⁵:
Clear case definitions
Identification of at-risk populations
Risk-adjusted data analysis (e.g. comorbidities, hospital case mix)
Structured feedback loops
These enable early detection, focused responses, and robust evaluation.
The Impacts of Surveillance
Surveillance has been shown to reduce infections — both alone and in combination with IPC interventions. The landmark SENIC study found that hospitals with surveillance programs and trained staff achieved up to 32% lower infection rates ⁶.
Further evidence:
UK: Mandatory ICU MRSA reporting led to a 97% reduction in infections⁷
USA: National surveillance contributed to a 16% reduction in HCAI rates over four years⁸
China: Real-time digital surveillance reduced MDRO infections by 21%⁹
Brazil: ICU collaborative surveillance cut bloodstream infections by 44%¹⁰
Europe: Electronic hand hygiene monitoring dropped BSI rates by 71%¹¹
Surveillance enables visibility and accountability, helping clinicians adhere to protocols and driving continuous improvement.
Selective Screening: A Cost-Effective Strategy
Selective screening — targeting high-risk patients or units — is among the most cost-effective IPC strategies. A recent umbrella review of 101 economic evaluations concluded that:
Selective screening consistently outperforms universal screening and no intervention, especially in lower-prevalence settings¹².
However, selective screening isn’t foolproof. More complex, and time varying risk-factors can mean typical risk based screenings miss infections - we still need improved
What Makes Surveillance Work?
Several factors influence the effectiveness of surveillance:
Prevalence level
Higher prevalence justifies broader, even universal screening¹⁶
Speed of response
Timely action on surveillance insights is critical — delays erode impact¹⁷
Targeted focus
Focus on high-risk populations — such as ICUs, oncology wards, and surgical units — see outsized benefits¹⁸
Data quality
Incomplete or inconsistent data (including use of wrong denominators or biased) undermines surveillance¹⁹
Integration with IPC bundles
Surveillance achieves greater impact when integrated with bundled interventions like hand hygiene, antimicrobial stewardship, and decolonisation therapies²⁰
Challenges and Limitations
Despite its proven value, today’s surveillance systems face significant limitations:
Underreporting and inconsistent definitions
Manual, error-prone workflows
Fragile in-house tools that break when data feeds change
Lack of scalability as data volume and complexity grow
To address these, we need:
Standardised, interoperable system
Intelligent automation to reduce the burden and errors
Scalable platforms that support real-time decision-making
Discussion
Surveillance is a clinical and operational enabler. The evidence demonstrates that structured surveillance results in fewer infections, faster responses, and better allocation of resources. Its impact is amplified when paired with bundled-IPC interventions, and feedback systems, however, even on its own, surveillance drives change by increasing awareness and accountability.
Challenges remain. Underreporting, limited infrastructure in certain seettings, and uneven or biased implementation weaken its potential, especially in low-resource settings. Balancing selective and broad approaches, ensuring data quality, and enabling timely action are critical to maximising its value.
Conclusion
In a world facing rising AMR and frequent outbreaks, surveillance is no longer optional — it is foundational.
You can’t reduce what you don’t measure.
References
